Guardant Health, Inc.
GH
Clasificación en acciones
#1081
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Precio por acción
$159.93
Última sincronización: 2026-10-19
Capitalización bursátil
$21.46B
Cambio (1 día)
0.84%
Cambio (1 año)
127.83%
País
US
Comercio Guardant Health, Inc. (GH)
Categoría
Healthcare
Ratio P/E de Guardant Health, Inc. (GH)
Ratio P/E al October 2026 TTM: -46.70
Según los últimos informes financieros y el precio de las acciones de Guardant Health, Inc., el P/E actual (TTM) de la empresa es -46.70. Al final de 2023, la empresa tenía un P/E de -6.32.
Historial del ratio P/E de Guardant Health, Inc. desde 2016 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -46.70 | 443.68% |
| 2024 | -8.59 | 36.01% |
| 2023 | -6.32 | 48.81% |
| 2022 | -4.25 | -83.00% |
| 2021 | -24.98 | -49.55% |
| 2020 | -49.52 | -47.09% |
| 2019 | -93.58 | 149.04% |
| 2018 | -37.58 | 37.33% |
| 2017 | -27.36 | 196.49% |
| 2016 | -9.23 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 36.15 | -177.42% |
US
|
|
| 39.77 | -185.16% |
US
|
|
| -290.26 | 521.51% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -173.20% |
US
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.